By Tiffany Hu ยท February 16, 2021, 9:44 PM EST
South Korean-based Daewoong Pharmaceuticals can keep its low-cost version of Allergan’s Botox treatment on the market while the Federal Circuit considers whether it should pause the U.S. International Trade Commission’s import…
To view the full article, register now.
